Effects of quetiapine on cognitive functions in schizophrenia

Akdede B., Alptekin K., Kitis A., Arkar H., Akvardar Y.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.29, no.2, pp.233-238, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 29 Issue: 2
  • Publication Date: 2005
  • Doi Number: 10.1016/j.pnpbp.2004.11.005
  • Journal Name: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.233-238
  • Keywords: cognitive function, quetiapine, schizophrenia, SYNDROME SCALE PANSS, NEUROPSYCHOLOGICAL DEFICITS, HALOPERIDOL, RISPERIDONE, CLOZAPINE, OLANZAPINE, ANTIPSYCHOTICS, IMPROVEMENT, FUMARATE, SEROQUEL
  • Marmara University Affiliated: No

Abstract

Objective: All atypical antipsychotic drugs with complex pharmacology have been shown to improve some, but not all, domains of cognitive function, including quetiapine, i.e., the agent with the most rapid dissociation from dopamine receptors and a relatively weak serotonin antagonism. The present study was to evaluate which, if any, areas of cognition improve in patients with schizophrenia, following a brief treatment with quetiapine.